Loading
A phase 1 trial of IMC-001 run by Mayo Clinic, terminated.
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study is a phase 1 interventional study registered as NCT05393713 by Mayo Clinic, with 3 participants enrolled, started 2022-10-17. Conditions recorded: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma and Recurrent Metastatic Melanoma. Interventions recorded: Anti-PD-L1 Monoclonal Antibody IMC-001 and Punch Biopsy.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares IMC-001, ImmuneOncia Therapeutics and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/